Comparison of 2 study groups of patients with relapsed or refractory AML treated on low-dose versus higher-dose decitabine schedules
Parameter . | Current study . | Higher-dose decitabine . |
|---|---|---|
| Decitabine, mg/m2/course | 50-300 | 750 |
| No. patients treated (%) | 32* | 17 |
| First salvage | ||
| CRD1, less than 12 mo | 11 (34) | 9 (53) |
| CRD1, more than 12 mo | 2 (6) | 3 (18) |
| Second or more salvage | 19 (59) | 5 (29) |
| No. responses, CR + other (%) | 5 + 3 (25) | 1 (6) |
| No. induction deaths (%) | 2 (6) | 3 (18) |
| Median age, y | 56 | 66 |
| Median WBC count | 2.8 | 4.9 |
| Favorable or intermediate cytogenetics (%) | 13/32 (41) | 7/15 (47) |
Parameter . | Current study . | Higher-dose decitabine . |
|---|---|---|
| Decitabine, mg/m2/course | 50-300 | 750 |
| No. patients treated (%) | 32* | 17 |
| First salvage | ||
| CRD1, less than 12 mo | 11 (34) | 9 (53) |
| CRD1, more than 12 mo | 2 (6) | 3 (18) |
| Second or more salvage | 19 (59) | 5 (29) |
| No. responses, CR + other (%) | 5 + 3 (25) | 1 (6) |
| No. induction deaths (%) | 2 (6) | 3 (18) |
| Median age, y | 56 | 66 |
| Median WBC count | 2.8 | 4.9 |
| Favorable or intermediate cytogenetics (%) | 13/32 (41) | 7/15 (47) |
WBC indicates white blood cell.
There were 2 patients registered and treated twice on the study at 2 different dose levels, having had a stem cell transplantation (and relapsed) in between the 2 registrations.